Colloidal bismuth subcitrate in peptic ulcer disease.
The pharmacological mechanism of ulcer coating and cytoprotection associated with colloidal bismuth have important therapeutic implications for the management of peptic ulcer disease. While the short-term healing rate is similar to that obtained by the H2 antagonists, the relapse rate appears lower.
D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001729:Bismuth / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy*; D006801:Humans; D009942:Organometallic Compounds; D010437:Peptic Ulcer / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate; D001729:Bismuth